|
|
Background: Long noncoding RNA (lncRNA)-mediated dysregulation is closely associated with various malignant tumors. However, the clinical significance of aberrant lncRNA expression in colorectal cancer (CRC) is still elusive.
Methods: Differentially expressed LINC01410 in CRC was detected by analyzing the data from The Cancer Genome Atlas (TCGA). The expression level of LINC01410 was identified in 18 pairs of CRC tissues by real-time PCR assay at our center. Real-time PCR was also used to detect the expression of serum LINC01410 in serum obtained from 51 patients with primary CRC, 38 patients with colorectal polyps, and 50 healthy controls. Correlation and receiver operating characteristic curves (ROC) of CRC patients from the TCGA and our center were also carried out to assess the predictive value of LINC01410.
Results: The relative expression level of LINC01410 in CRC tissues and matched adjacent normal tissues was 2.268 (1.518, 3.359) and 0.962 (0.661, 1.719) (p < 0.05). Serum LINC01410 in CRC, colorectal polyps, and healthy control groups were 2.191 (1.505, 3.145), 1.665 (1.282, 2.237), and 1.000 (0.787, 1.227), respectively (p < 0.05). LINC01410 expression correlated with lymph node metastasis and TNM stages (p < 0.05). ROC curves revealed its significant diagnostic value in CRC, which was better than CEA and CA199. A new model combining LINC01410, CEA, and CA199 yielded a good diagnostic efficacy for CRC patients, showing the highest sensitivity and AUC.
Conclusions: Our study demonstrated that LINC01410 was upregulated in CRC and the high expression of LINC01410 was associated with poor prognosis, suggesting its possible role as a potential marker for CRC.
DOI: 10.7754/Clin.Lab.2020.200805
|
